![GRAPHIC](https://www.sec.gov/Archives/edgar/data/1795579/000110465924051960/tm2412634d1_ex99-1img011.jpg)
| The 15 largest shareholders as of December 31, 2023
Shareholders
Total
number of
shares Holding, % Votes, %
BVF Partners LP 6,260,311 10,51% 11,67%
Linc AB 5,962,312 10,01% 11,11%
Calliditas Therapeutics AB 5,908,018 9,92% 0,00%
Stiftelsen Industrifonden 3,145,440 5,28% 5,86%
Avanza Pension 2,096,247 3,52% 3,91%
Polar Capital 2,000,000 3,36% 3,73%
Unionen 1,971,692 3,31% 3,67%
Handelsbanken Fonder 1,773,542 2,98% 3,30%
Fourth Swedish National
Pension Fund 1,754,603 2,94% 3,27%
Sofinnova Partners 1,408,078 2,36% 2,62%
Öhman Fonder 1,329,142 2,23% 2,48%
The Invus Group 1,068,115 1,79% 1,99%
Hans Edvin Öhman 885,554 1,49% 1,65%
Renée Aguiar-Lucander 643,000 1,08% 1,20%
BlackRock 606,741 1,02% 1,13%
Top 15 largest shareholders 36,812,795 61,79% 57,58%
Other shareholders 22,767,292 38,21% 42,42%
Total share 59,580,087 100,00% 100,00%
CALTX share data 2023
Average daily turnover (SEK) 31,167,394
Average daily turnover rel. mcap 0.50%
Average daily shares traded 298,093
Number of shares traded 74,821,405
Average trades per day 1890
Number of trades 474,507
Average value per trade 16,487
High 141.90
Low 80.80
Volume-Weighted Average Price (VWAP) 104.56
Size classes as of December 31, 2023
Size classes
No. of known
shareholders No. of shares Holding, % Votes, %
Proportion of known
shareholders
1 - 100 9,418 353,517 0,59% 0,59% 50,08%
101 - 200 2,395 375,309 0,63% 0,63% 12,73%
201 - 300 1,363 351,258 0,59% 0,59% 7,25%
301 - 400 840 304,475 0,51% 0,51% 4,47%
401 - 500 817 388,031 0,65% 0,65% 4,34%
501 - 1,000 1,707 1,328,955 2,23% 2,23% 9,08%
1,001 - 2,000 1,046 1,579,325 2,65% 2,65% 5,56%
2,001 - 5,000 711 2,285,700 3,84% 3,84% 3,78%
5,001 - 10,000 260 1,925,868 3,23% 3,23% 1,38%
10,001 - 20,000 111 1,606,124 2,70% 2,70% 0,59%
20,001 - 50,000 75 2,392,718 4,02% 4,02% 0,40%
50,001 - 100,000 26 1,754,164 2,94% 2,94% 0,14%
100,001 - 500,000 21 4,323,482 7,26% 7,26% 0,11%
500,001 - 1,000,000 5 3,174,197 5,33% 5,33% 0,03%
1,000,001 - 5,000,000 9 16,546,859 27,77% 27,77% 0,05%
5,000,001 - 10,000,000 3 18,130,641 30,43% 30,43% 0,02%
10,000,001 - 50,000,000 0 0 0,00% 0,00% 0,00%
50,000,001 - 0 0 0,00% 0,00% 0,00%
Unknown holding size 0 2,759,464 4,63% 4,62% 0,00%
Total 18,807 59580087 100,00% 100,00% 100,00%
Analysts
Calliditas is monitored by Bryan Garnier & Co, Carn-egie, Citi, Guggenheim, H.C Wainwright & Co, Jefferies,
Kempen & Co, Kepler Cheuvreux, LifeSci Capital, Pareto
Securities, SEB and Stifel.
Outlook 2024
For 2024, Calliditas expects continued revenue growth:
Total net sales from the Nefecon franchise, including
milestones, are estimated to be USD 150-180 million
for the year ending December 31, 2024.
11Calliditas Therapeutics | Annual Report 2023 |